Q1 2024 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2024-05-14 · accession 0000950123-24-005045
$155.0M
Reported value
11
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67080N101 | NUVB | Nuvation Bio | $51.2M | 33.0% | 14,072,340 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics | $36.9M | 23.8% | 2,355,904 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $24.5M | 15.8% | 3,001,319 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $18.2M | 11.8% | 1,076,357 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $8.4M | 5.44% | 843,750 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Holding | $5.6M | 3.63% | 159,846 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $3.2M | 2.06% | 2,249,123 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $2.4M | 1.52% | 1,788,160 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $1.9M | 1.21% | 360,903 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $1.3M | 0.87% | 251,270 | Common | SOLE |
| 50107A104 | KRON1USD | Kronos Bio | $1.2M | 0.80% | 955,866 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.